about
Human papillomavirus and cervical cancer: biomarkers for improved prevention effortsSequence variation in the E2-binding domain of HPV16 and biological function evaluation in Tunisian cervical cancers.Human papillomavirus vaccine: a boon or curse.Comparison of the performance of rapid prescreening, 10% random review, and clinical risk criteria as methods of internal quality control in cervical cytopathology.Liquid-based cytology and cell block immunocytochemistry in veterinary medicine: comparison with standard cytology for the evaluation of canine lymphoid samples.Performance of the DNA-Citoliq liquid-based cytology system compared with conventional smears.Pap test in a high-risk population comparison of conventional and liquid-base cytology
P2860
Q27023127-4048BF2B-B411-4662-819C-B0DAC3C12112Q33852197-782C8BFC-9989-47C0-8D82-12F0C228FBE0Q35886746-7F1B396A-6A26-434D-BEFD-76AD708E1653Q37153685-DEC9F6E4-1E3D-44E1-B6CF-A8730746403EQ53622078-25DAFD51-9572-40D2-90F4-8DF6BCADA10FQ58850519-37547350-D774-4547-817C-0460C8429A25Q58850531-4F8EA76E-95B5-4080-A3DD-EC2D73361676
P2860
description
im Jahr 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 January 2001
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2001
@uk
name
Cervical-cancer screening beyond the year 2000
@en
Cervical-cancer screening beyond the year 2000
@nl
type
label
Cervical-cancer screening beyond the year 2000
@en
Cervical-cancer screening beyond the year 2000
@nl
prefLabel
Cervical-cancer screening beyond the year 2000
@en
Cervical-cancer screening beyond the year 2000
@nl
P1433
P1476
Cervical-cancer screening beyond the year 2000
@en
P2093
A Ferenczy
P356
10.1016/S1470-2045(00)00192-3
P577
2001-01-01T00:00:00Z